Although previous data demonstrated the ability of the anti-TRAIL antibody to cross the blood–brain barrier (BBB) and reach the brain of the 3xTg-AD mice after its intraperitoneal injection [11], the adoption of innovative systems and a direct route for brain drug delivery could be a valuable strategy to increase its therapeutic efficacy. Here, TNFSF10 is linked to Alzheimer disease.